KARD (Kardigan) 3-1 Month Momentum %: N/A% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
11 GF Score
Price $20.49
! 1 Warning Sign
View Full Analysis

What is Kardigan 3-1 Month Momentum %?

Kardigan KARD +3.13% 11 3-1 Month Momentum % is N/A% as of Aug. 04, 2026. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,393 Biotechnology companies, Kardigan ranks worse than 71787.44% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-04), Kardigan's 3-1 Month Momentum % is N/A%.

The industry rank for Kardigan's 3-1 Month Momentum % or its related term are showing as below:

KARD's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -6.97
* Ranked among companies with meaningful 3-1 Month Momentum % only.

Kardigan  (NAS:KARD) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Kardigan 3-1 Month Momentum % Related Terms

KARD
11GF Score
Kardigan Inc KARD
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan  (NAS:KARD) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
Kardigan (KARD) has a 3-1 Month Momentum % of N/A% as of Aug. 04, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Kardigan and its competitors. According to the industry distribution chart, Kardigan ranks #999999 out of 1393 companies in the Biotechnology industry.
Is Kardigan's 3-1 Month Momentum % too high?
Kardigan's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Kardigan ranks #999999 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's 3-1 Month Momentum % compare to OCUL and GHRS?
According to the Biotechnology industry distribution chart, Kardigan ranks #999999 out of 1393 companies for 3-1 Month Momentum %. This places Kardigan in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Kardigan and its competitors. Kardigan's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Kardigan (KARD), the current 3-1 Month Momentum % is N/A% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score

Get the complete analysis for KARD

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.49
Price